Physician profile
Vuthy Leng
NPI 1710952379
$1,516.05
in general payments reported to CMS, 2019-2025
23 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $71.12 · 2020: $376 · 2021: $702 · 2022: $134 · 2023: $14.74 · 2024: $95.43 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $233.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $425.51 | 2020-2022 | |
| Orexo US, INC. | $262.57 | 2020-2025 | Zubsolv |
| Glaxosmithkline, LLC. | $114.43 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.97 | 2019-2021 | |
| Pfizer INC. | $72.19 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $71.97 | 2024-2025 | Voquezna |
| Amarin Pharma, INC. | $62.96 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $54.43 | 2021 | |
| Gilead Sciences, INC. | $35.71 | 2021 | |
| Abbott Laboratories | $35.55 | 2021-2022 | |
| Linus Health, INC. | $31.47 | 2024 | Core Cognitive Evaluation |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.39 | 2019-2025 | Relistor |
| Eisai INC. | $30.48 | 2020 | |
| Allergan, INC. | $28.81 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $23.74 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Titan Pharmaceuticals, INC. | $22.69 | 2020 | |
| Astellas Pharma US INC | $22.57 | 2021 | |
| Lilly USA, LLC | $16.89 | 2025 | Mounjaro |
| Medtronic, INC. | $15.39 | 2021 | |
| Novo Nordisk INC | $14.74 | 2023 | Wegovy |
| Janssen Pharmaceuticals, INC | $14.11 | 2020 | |
| Aimmune Therapeutics, INC. | $14.00 | 2025 | Zenpep |
| Grifols USA, LLC | $12.48 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vuthy Leng listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.